Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of the hepatokine fetuin-A

Tae Woo Jung, Byung Soo Youn, Hyuk Soon Choi, So Young Lee, Ho Cheol Hong, Sae Jeong Yang, Hye Jin Yoo, Baek Hui Kim, Sei Hyun Baik, Kyung Mook Choi

Research output: Contribution to journalArticlepeer-review

65 Citations (Scopus)


Fetuin-A was recently identified as a novel hepatokine which is associated with obesity, insulin resistance and non-alcoholic fatty liver disease. Salsalate, a prodrug of salicylate with an anti-inflammatory effect and lower side effect profile, significantly lowers glucose and triglyceride levels, and increased adiponectin concentrations in randomized clinical trials. In this study, we examined the effects and regulatory mechanisms of salsalate and full length-adiponectin (fAd) on fetuin-A expression, steatosis and lipid metabolism in palmitate-treated HepG2 cells. Incubation of hepatocytes with palmitate significantly increased fetuin-A and SREBP-1c expression which lead to steatosis and knock-down of fetuin-A by siRNA restored these changes. Salsalate significantly down-regulated palmitate-induced fetuin-A mRNA expression and secretion in a dose- and time-dependent manner. Inhibition of palmitate-induced fetuin-A by salsalate was mediated by AMPK-mediated reduction of NFκB activity, which was blocked by AMPK siRNA or an inhibitor of AMPK. Salsalate attenuated the excessive steatosis by palmitate through SREBP-1c regulation in hepatocytes. Furthermore, fAd also showed suppression of palmitate-induced fetuin-A through the AMPK pathway and improvement of steatosis accompanied by restoration of SREBP-1c, PAPR-α and CD36. In preliminary in vivo experiments, salsalate treatment inhibited high fat diet (HFD)-induced steatosis as well as fetuin-A mRNA and protein expression in SD rats. In conclusion, salsalate and fAd improved palmitate-induced steatosis and impairment of lipid metabolism in hepatocytes via fetuin-A inhibition through the AMPK-NFκB pathway. AbbreviationsNAFLDnon-alcoholic fatty liver diseaseAMPKadenosine monophosphate-activated protein kinaseNF-κBnuclear factor-κBfAdfull- length adiponectinHFDhigh fat dietEMSAelectrophoretic mobility-shift assayChIPchromatin immunoprecipitation assay.

Original languageEnglish
Pages (from-to)960-969
Number of pages10
JournalBiochemical Pharmacology
Issue number7
Publication statusPublished - 2013


  • AMPK
  • Adiponectin
  • Fetuin-A
  • Hepatokine
  • NFκB
  • Non-alcoholic fatty liver disease
  • Salicylate
  • Salsalate

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology


Dive into the research topics of 'Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of the hepatokine fetuin-A'. Together they form a unique fingerprint.

Cite this